Atlas Trials

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

Clinical trial NCT06566391 · UNKNOWN

Trial details

NCT number
NCT06566391
Sponsor
European Institute of Oncology
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2019-03-05
Primary completion
2024-12-31
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.